Anavex Life Sciences Corp. (AVXL)
NASDAQ: AVXL · Real-Time Price · USD
4.340
-0.060 (-1.36%)
At close: Dec 8, 2025, 4:00 PM EST
4.272
-0.069 (-1.58%)
Pre-market: Dec 9, 2025, 8:39 AM EST
Anavex Life Sciences Employees
Anavex Life Sciences had 34 employees as of September 30, 2025. The number of employees decreased by 8 or -19.05% compared to the previous year.
Employees
34
Change (1Y)
-8
Growth (1Y)
-19.05%
Revenue / Employee
n/a
Profits / Employee
-$1,364,029
Market Cap
387.77M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 34 | -8 | -19.05% |
| Sep 30, 2024 | 42 | 2 | 5.00% |
| Sep 30, 2023 | 40 | 2 | 5.26% |
| Sep 30, 2022 | 38 | 13 | 52.00% |
| Sep 30, 2021 | 25 | 5 | 25.00% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
AVXL News
- 5 days ago - AVXL Investors Have Opportunity to Join Anavex Life Sciences Corp. Fraud Investigation with the Schall Law Firm - Business Wire
- 13 days ago - Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference - GlobeNewsWire
- 13 days ago - Anavex Life Sciences Corp. (AVXL) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 14 days ago - Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update - GlobeNewsWire
- 20 days ago - Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference - GlobeNewsWire
- 21 days ago - Anavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025 - GlobeNewsWire
- 25 days ago - Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease - GlobeNewsWire
- 5 weeks ago - Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Control Group - GlobeNewsWire